Federated Hermes
OTLK icon

Federated Hermes’s Outlook Therapeutics OTLK Stock Holding History

Federated Hermes’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-477
Closed -$902 – 2165
2024
Q4 		$902 Sell
477
-90,942
-99% -$374K ﹤0.01% 2023
2024
Q3 		$488K Buy
+91,419
New +$669K ﹤0.01% 1338

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes's OTLK Position: Q1 2025 in Review

Federated Hermes sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 477 shares — an estimated $902 sold.

Federated Hermes first reported a position in OTLK in Q3 2024 and held it in 2 quarters. The position peaked at $488K in Q3 2024. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

  • Federated Hermes reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Federated Hermes sold 477 Outlook Therapeutics shares in Q1 2025, an estimated $902.
  • Federated Hermes first reported a position in Outlook Therapeutics in Q3 2024 and held it in 2 quarters.
  • Federated Hermes's Outlook Therapeutics position peaked at $488K in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.